NAS · US · liminatuspharma.com
0.0583USD+24.04%Mkt Cap: —P/E: —2d ago
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phas…
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-10.21M $
Revenue/Share—
Last Price0.0583 USD
Fiscal Year End—
MR Quarter—
Employees1
CountryUS
Sector—
Industry—
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B11.66
EPS (TTM)—
EPS (Forward)—
52W Range
0.041041% of range0.0833
52W High0.0833 USD
52W Low0.0410 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE103.99%
ROA-1990.37%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-9.96M $
CapEx (TTM)13.11K $
FCF Margin—
FCF Yield—
Net Debt-1.57M $
Net Debt/EBITDA0.39
Balance Sheet
Debt/Equity-0.15
Current Ratio1.12
Quick Ratio0.99
Book Value/Sh0.0050 USD
Cash/Share0.0450 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float35.44M
Insiders—
Institutions—
Technical
SMA 50—
SMA 200—
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)1.24K
Avg Vol (10d)—
Technical Indicators
RSI (14)51.7
MACD-0.0024
MACD Signal-0.0016
MACD Hist.-0.0007
BB Upper0.0690 USD
BB Middle0.0571 USD
BB Lower0.0452 USD
BB Width41.68%
ATR (14)0.0070 USD
Vol Ratio (20d)21.63x